EA201170131A1 - Соединения антагонистов phk для ингибирования экспрессии митохондриальной глицерин-3-фосфатацилтрансферазы 1 (mtgpat1) - Google Patents
Соединения антагонистов phk для ингибирования экспрессии митохондриальной глицерин-3-фосфатацилтрансферазы 1 (mtgpat1)Info
- Publication number
- EA201170131A1 EA201170131A1 EA201170131A EA201170131A EA201170131A1 EA 201170131 A1 EA201170131 A1 EA 201170131A1 EA 201170131 A EA201170131 A EA 201170131A EA 201170131 A EA201170131 A EA 201170131A EA 201170131 A1 EA201170131 A1 EA 201170131A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mtgpat1
- phosphataciltransferase
- phk
- mitochondrial
- glycerin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 230000002438 mitochondrial effect Effects 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01015—Glycerol-3-phosphate O-acyltransferase (2.3.1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7794208P | 2008-07-03 | 2008-07-03 | |
| EP08104623 | 2008-07-03 | ||
| PCT/EP2009/057907 WO2010000656A1 (en) | 2008-07-03 | 2009-06-24 | Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201170131A1 true EA201170131A1 (ru) | 2011-08-30 |
Family
ID=41066150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170131A EA201170131A1 (ru) | 2008-07-03 | 2009-06-24 | Соединения антагонистов phk для ингибирования экспрессии митохондриальной глицерин-3-фосфатацилтрансферазы 1 (mtgpat1) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120004276A1 (enExample) |
| EP (1) | EP2310504A1 (enExample) |
| JP (1) | JP2011526482A (enExample) |
| KR (1) | KR20110031368A (enExample) |
| CN (1) | CN102076854A (enExample) |
| AU (1) | AU2009265836A1 (enExample) |
| BR (1) | BRPI0915837A2 (enExample) |
| CA (1) | CA2729897A1 (enExample) |
| EA (1) | EA201170131A1 (enExample) |
| MX (1) | MX2010013552A (enExample) |
| WO (1) | WO2010000656A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2585596T3 (pl) * | 2010-06-23 | 2021-06-28 | Curna, Inc. | Leczenie chorób związanych z podjednostką alfa kanału sodowego bramkowanego napięciem (SCNA) poprzez hamowanie naturalnego transkryptu antysensownego SCNA |
| DK2638163T3 (en) | 2010-11-12 | 2017-07-24 | Massachusetts Gen Hospital | POLYCOMB-ASSOCIATED NON-CODING RNAs |
| WO2012103520A1 (en) * | 2011-01-28 | 2012-08-02 | Board Of Regents Of The University Of Nebraska | Methods and compositions for modulating cyclophilin d |
| WO2013173652A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| ES2724853T3 (es) | 2012-11-15 | 2019-09-16 | Roche Innovation Ct Copenhagen As | Conjugados de oligonucleótidos |
| MY177989A (en) * | 2013-01-30 | 2020-09-28 | Hoffmann La Roche | Lna oligonucleotide carbohydrate conjugates |
| CN105039513B (zh) * | 2015-05-29 | 2018-12-28 | 广州市第一人民医院 | 用于非酒精性脂肪肝相关目的基因多态性检测方法及其引物，以及试剂盒 |
| CN104997768B (zh) * | 2015-07-23 | 2017-11-17 | 上海市第六人民医院 | 鱼藤酮在制备降血糖药物中的应用 |
| EP4162033A4 (en) * | 2020-06-09 | 2024-12-25 | Alnylam Pharmaceuticals, Inc. | Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression |
| GB202015056D0 (en) * | 2020-09-23 | 2020-11-04 | Cambridge Entpr Ltd | Biomarkers |
| WO2022182985A1 (en) * | 2021-02-27 | 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (gpam) inhibitors |
| JP2024539097A (ja) * | 2021-10-22 | 2024-10-28 | アムジェン インコーポレイテッド | Ｇｐａｍ発現を阻害するためのｒｎａｉコンストラクト及びその使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002364900A1 (en) * | 2001-11-30 | 2003-06-17 | Bristol-Myers Squibb Company | Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof |
| US20050053981A1 (en) * | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| US8178503B2 (en) * | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
-
2009
- 2009-06-24 WO PCT/EP2009/057907 patent/WO2010000656A1/en not_active Ceased
- 2009-06-24 US US13/000,974 patent/US20120004276A1/en not_active Abandoned
- 2009-06-24 JP JP2011515374A patent/JP2011526482A/ja not_active Withdrawn
- 2009-06-24 EP EP20090772356 patent/EP2310504A1/en not_active Withdrawn
- 2009-06-24 MX MX2010013552A patent/MX2010013552A/es not_active Application Discontinuation
- 2009-06-24 CA CA2729897A patent/CA2729897A1/en not_active Abandoned
- 2009-06-24 KR KR1020117002768A patent/KR20110031368A/ko not_active Withdrawn
- 2009-06-24 CN CN200980124993.0A patent/CN102076854A/zh active Pending
- 2009-06-24 EA EA201170131A patent/EA201170131A1/ru unknown
- 2009-06-24 AU AU2009265836A patent/AU2009265836A1/en not_active Abandoned
- 2009-06-24 BR BRPI0915837A patent/BRPI0915837A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102076854A (zh) | 2011-05-25 |
| US20120004276A1 (en) | 2012-01-05 |
| AU2009265836A1 (en) | 2010-01-07 |
| JP2011526482A (ja) | 2011-10-13 |
| WO2010000656A1 (en) | 2010-01-07 |
| BRPI0915837A2 (pt) | 2015-11-03 |
| KR20110031368A (ko) | 2011-03-25 |
| MX2010013552A (es) | 2011-03-24 |
| EP2310504A1 (en) | 2011-04-20 |
| CA2729897A1 (en) | 2010-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201170131A1 (ru) | Соединения антагонистов phk для ингибирования экспрессии митохондриальной глицерин-3-фосфатацилтрансферазы 1 (mtgpat1) | |
| EA201190325A1 (ru) | Специфичные к меланокортиновым рецепторам пептиды | |
| MX2011005965A (es) | Conjugados de leptina y de análogos de leptina y sus usos de los mismos. | |
| SV2011003829A (es) | Derivados de pirazolo [3,4] pirimidin-4-ilo y sus usos para el tratamiento de la diabetes y la obesidad | |
| ECSP13012661A (es) | Composición farmacéutica, métodos de tratamiento y usos de la misma. | |
| WO2008040548A3 (en) | Treatment for non-alcoholic-steatohepatitis | |
| CL2011001082A1 (es) | Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2. | |
| NZ598294A (en) | Heterocyclic compounds for the inhibition of pask | |
| EA201490913A1 (ru) | Лекарственные формы для лечения сахарного диабета | |
| CL2008001126A1 (es) | Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad. | |
| MX2012006734A (es) | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas. | |
| CL2008003582A1 (es) | Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash). | |
| ECSP11010760A (es) | Derivados de quinoxalindiona | |
| CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
| MX362375B (es) | Extracto de saliva entera de sanguijuela. | |
| WO2015095354A3 (en) | Compositions and methods for treating fatty tissue buildup | |
| ATE442349T1 (de) | Diacylglycerol-acyltransferase-hemmer | |
| PH12014501442B1 (en) | Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof | |
| WO2008079610A3 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
| MX2010003440A (es) | Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo. | |
| WO2011041385A3 (en) | Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis | |
| PH12014501441A1 (en) | Derivatives of aza adamantane and uses thereof | |
| EA201301308A1 (ru) | Комбинация для лечения сахарного диабета | |
| EA201000926A1 (ru) | Пиперазины в качестве агентов против ожирения | |
| CL2011001777A1 (es) | Composicion farmaceutica que contiene aleglitazar; proceso para preparar dicha composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes tipo ii o enfermedades cardiovasculares. |